Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsblue cross blue shield - louisiana Humira Prior Au…
    Ask Trek AI about this page
    Currentblue cross blue shield - louisianaPolicy N/A

    Humira (adalimumab) biosimilar coverage

    Customize your policy alerts

    Sign up for all blue cross blue shield - louisiana policy alerts

    Know when blue cross blue shield - louisiana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Describes 2025 coverage guidance for Humira and preferred adalimumab biosimilars for Blue Advantage (HMO/PPO) members, including prior authorization and interchangeability notes that affect prescribers, pharmacists, and members.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyHumira (adalimumab) biosimilar coverage
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization request for all new adalimumab prescriptions; approved Humira authorizations apply to preferred biosimilars and switching.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2025coverage year
    Blue Advantageaffected plan(s)
    All new prescriptionsprior auth
    Approved Humira authsapplies to biosimilars

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior authorization required for all new adalimumab prescriptions

    All new adalimumab prescriptions require prior authorization before coverage; approved Humira authorizations apply to preferred adalimumab biosimilars and switching between preferred adalimumab products does not require a new authorization.

    Note

    Approved Humira authorizations cover switching to preferred biosimilars

    Members with an approved authorization for Humira do not require a new prior authorization to switch to any other preferred adalimumab product listed in this guide.

    Documentation Required

    Required prior authorization documentation for new adalimumab starts

    Providers must submit a prior authorization request for all new adalimumab prescriptions; existing approvals for Humira extend to preferred adalimumab biosimilars and do not require a new prior authorization when switching.

    Denial Risk

    Coverage will be denied until prior authorization is approved

    Failure to submit a prior authorization request for new adalimumab prescriptions will prevent coverage until an authorization is approved.

    Initial Therapy Coverage Criteria

    Initial Therapy Criteria

    Covered when ALL of the following are met:

    Initial adalimumab therapy: All new adalimumab prescriptions require prior authorization review before coverage.

    Approved prior authorizations for Humira apply to preferred adalimumab biosimilars; members with an approved Humira authorization do not require a new prior authorization to switch to any other preferred adalimumab product listed in this guide.

    Humira and Biosimilar Coverage

    Billing Rule

    Preferred Humira biosimilar (Yuflyma)

    Yuflyma® (adalimumab) is listed as a preferred Humira biosimilar on the Blue Advantage formularies for 2025.

    Definitions

    inv-06: Biosimilar — Definition (FDA reference)
    DefinitionA biosimilar is a biological product that is highly similar to an existing FDA‑approved biological product (the reference product) with no clinically meaningful differences in safety, efficacy, purity, and potency.
    Relation to reference productHas the same route of administration, strength, dosage, treatment benefits, and potential side effects as the reference product.
    Clinical equivalenceNo clinically meaningful differences in safety or efficacy compared with the reference product.
    Cost implicationTypically less expensive than the reference product, offering a more affordable treatment option.
    inv-07: Interchangeable biosimilar — Definition and Louisiana pharmacy substitution law
    DefinitionAn interchangeable biosimilar meets additional requirements allowing substitution for the reference product at the pharmacy without consulting the prescriber before filling.
    Louisiana law — patient consentLouisiana law requires the patient’s consent before an interchangeable biosimilar may be substituted.
    Louisiana law — prescriber notificationThe pharmacist must notify the prescriber within 5 business days of the dispense date when an interchangeable biosimilar is substituted.
    Practical impactInterchangeable products can be substituted at the pharmacy level, which may facilitate switching and potentially reduce costs for members.

    Background

    Adalimumab (Humira) is a tumor necrosis factor (TNF) inhibitor indicated for multiple inflammatory and autoimmune conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. These biologic therapies are large, complex molecules produced from living cells and are administered parenterally.

    Biosimilars to adalimumab are biological products that are highly similar to the FDA‑approved reference product with no clinically meaningful differences in safety, efficacy, purity, or potency. They share the same route of administration, strength, dosage, treatment benefits, and potential side effects as the reference product and can provide lower‑cost alternatives to Humira.

    Some biosimilars may be designated as interchangeable, meaning they meet additional regulatory requirements allowing pharmacy‑level substitution for the reference product. Note that Louisiana law requires patient consent and pharmacist notification to the prescriber within 5 business days after dispensing when an interchangeable biosimilar is substituted.

    For 2025 Blue Advantage members, Humira and selected preferred adalimumab biosimilars are covered under the formulary; however, all new adalimumab prescriptions require prior authorization before coverage, and existing approvals for Humira apply to preferred biosimilars when switching among preferred products.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyHumira (adalimumab) biosimilar coverage
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization request for all new adalimumab prescriptions; approved Humira authorizations apply to preferred biosimilars and switching.
    SourceLink
    On This Page
    Provider Actions and Authorization RequirementsInitial Therapy Coverage CriteriaHumira and Biosimilar CoverageDefinitionsBackground